Literature DB >> 31033672

Prophylaxis in High-Risk Patients With eGFR < 30 mL/min/1.73 m2: Get the Balance Right.

Estelle C Nijssen1, Patty J Nelemans2, Roger J Rennenberg3, Ralph A Theunissen4, Vincent van Ommen4, Joachim E Wildberger1.   

Abstract

OBJECTIVES: Clinical guidelines recommend prophylactic intravenous fluids for patients with estimated glomerular filtration rate (eGFR) less than 30 mL/min/1.73 m to prevent adverse postcontrast outcomes. These patients represent a small minority of the population receiving intravascular iodinated contrast material, and data are not readily available. The current study aim is to gain insight into positive and negative effects of prophylaxis by comparing postcontrast outcomes in high-risk patients who did and did not receive prophylaxis.
MATERIALS AND METHODS: Observational data were gathered over 4 years. Inclusion criteria were age 18 years or older, eGFR less than 30 mL/min/1.73 m, and elective intravascular iodinated contrast administration. Exclusion criteria were dialysis and nonstandard periprocedural prophylaxis. Primary outcome was postcontrast acute kidney injury (>25% or >44 μmol/L serum creatinine increase within 2-5 days). Secondary outcomes were change in eGFR, 5 mL/min/1.73 m or greater eGFR decline, dialysis, and mortality at 1 month postcontrast including primary cause, as well as complications of prophylaxis. Results were stratified by contrast procedure type and corrected for potential confounders.
RESULTS: Of all 55,474 elective procedures with intravascular contrast administration, 362 patients met the inclusion criteria: 281 (78%) received standard 0.9% NaCl prophylaxis and 81 (22%) received no prophylaxis. Prophylaxis versus no prophylaxis adjusted odds ratios were nonsignificant and less than 1 for postcontrast renal outcomes (postcontrast acute kidney injury, eGFR decline, dialysis), indicating a trend toward a protective effect of prophylaxis. For mortality, adjusted odds ratios were nonsignificant and greater than 1, indicating a trend toward higher mortality risk after prophylaxis. Of the primary causes of death analyzed in prophylaxis patients, 24% (5/21) were related to prophylaxis. Among 281 prophylaxis patients, 18 (6.4%) complications of prophylaxis occurred: 15 heart failures and 3 arrhythmias.
CONCLUSIONS: Based on this study, no standard recommendation with regard to giving or withholding prophylaxis can be given. Prophylactic fluids may confer some protection against postcontrast renal adverse events but may also contribute toward increased risk of short-term death. In this setting, benefits and risks of prophylaxis must be carefully weighed and cardiac parameters assessed for each individual patient.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31033672     DOI: 10.1097/RLI.0000000000000570

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  4 in total

1.  Is There a Nonlinear Relationship between Serum Uric Acid and Lipids in a Hypertensive Population with eGFR ≥30 ml/min/1.73 m2? Findings from the China Hypertension Registry Study.

Authors:  Yu Yu; Xiao Huang; Minghui Li; Congcong Ding; Lihua Hu; Xiao Zhong; Wei Zhou; Tao Wang; Lingjuan Zhu; Huihui Bao; Xiaoshu Cheng
Journal:  Int J Endocrinol       Date:  2020-09-18       Impact factor: 3.257

2.  Impact on clinical practice of updated guidelines on iodinated contrast material: CINART.

Authors:  E C Nijssen; P J Nelemans; R J Rennenberg; A J van der Molen; G V van Ommen; J E Wildberger
Journal:  Eur Radiol       Date:  2020-02-27       Impact factor: 5.315

3.  Efficacy of brain natriuretic peptide vs. nicorandil in preventing contrast-induced nephropathy: a network meta-analysis.

Authors:  Ziwei Mei; Songmei Luo; Peipei Chen; Qiankun Zhang; Limei Zhou; Chaoyong Zhu; Hong Zhu; Lie Jin
Journal:  PeerJ       Date:  2022-02-23       Impact factor: 2.984

Review 4.  [Korean Clinical Practice Guidelines for Adverse Reactions to Intravenous Iodinate and MRI-Gadolinium Contrast Agents: Revised Clinical Consensus and Recommendations (3rd Edition, 2022)].

Authors:  Se Won Oh; So Young Park; Hwan Seok Yong; Young Hun Choi; Min Jae Cha; Tae Bum Kim; Ji Hyang Lee; Sae Hoon Kim; Jae Hyun Lee; Gyu Young Hur; Jae Yeon Hwang; Sejoong Kim; Hyo Sang Kim; Ji Young Ryu; Miyoung Choi; Chi-Hoon Choi
Journal:  Taehan Yongsang Uihakhoe Chi       Date:  2022-03-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.